INCYTE CORP (INCY) Form 10-Q — Oct 29, 2026
Incyte's Q3 2026 revenue rose 14% year-over-year to $1.56 billion, driven by JAKAFI volume growth (+$102.8M), JAKAFI XR launch, and record JAKAVI royalty revenue of $132.5M from Novartis. However, the company reported a quarterly net loss of $784.8 million (-$3.86 per share) versus net income of $424.2 million a year ago. The loss was driven almost entirely by a one-time $1.23 billion non-deductible IPR&D charge from the July 2026 acquisition of Vega Therapeutics ($1.25B cash) for latarcibart, a Phase 3 antibody for von Willebrand disease. Star Therapeutics can earn up to $750M in additional milestone payments.
Key figures
- Revenue
- 1557204000
- Total Debt
- 0
- Revenue Yoy
- 14.0% (Q3 2026 vs Q3 2025: $1,557.2M vs $1,366.0M)
- Total Assets
- 7287257000
- Cash Position
- 3275881000
- Shares Outstanding
- 203832492
- Q3 net sales
- 1316413000
- Vega iprd expense
- 1232000000
- Effective tax rate q3
- -13.9%
- Nine month net income
- 104132000
- Q3 total revenues 2025
- 1365980000
- Nine month total revenues
- 4503919000
- Vega contingent milestones
- $750M potential
- Effective tax rate nine months
- 74.4%
- Opzelura cms settlement benefit
- 246000000
- Vega acquisition cash consideration
- 1250000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.